DE3783122T2 - Verwendung von rekombiniertem menschlichem alpha-interferon zur herstellung eines arzneimittels zur behandlung des aids-virus. - Google Patents

Verwendung von rekombiniertem menschlichem alpha-interferon zur herstellung eines arzneimittels zur behandlung des aids-virus.

Info

Publication number
DE3783122T2
DE3783122T2 DE8787309312T DE3783122T DE3783122T2 DE 3783122 T2 DE3783122 T2 DE 3783122T2 DE 8787309312 T DE8787309312 T DE 8787309312T DE 3783122 T DE3783122 T DE 3783122T DE 3783122 T2 DE3783122 T2 DE 3783122T2
Authority
DE
Germany
Prior art keywords
interferon
alpha
htlv
iii
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE8787309312T
Other languages
German (de)
English (en)
Other versions
DE3783122D1 (de
Inventor
Judith Feinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25446188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3783122(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DE3783122D1 publication Critical patent/DE3783122D1/de
Publication of DE3783122T2 publication Critical patent/DE3783122T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE8787309312T 1986-10-22 1987-10-21 Verwendung von rekombiniertem menschlichem alpha-interferon zur herstellung eines arzneimittels zur behandlung des aids-virus. Revoked DE3783122T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92192286A 1986-10-22 1986-10-22

Publications (2)

Publication Number Publication Date
DE3783122D1 DE3783122D1 (de) 1993-01-28
DE3783122T2 true DE3783122T2 (de) 1993-04-22

Family

ID=25446188

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787309312T Revoked DE3783122T2 (de) 1986-10-22 1987-10-21 Verwendung von rekombiniertem menschlichem alpha-interferon zur herstellung eines arzneimittels zur behandlung des aids-virus.

Country Status (8)

Country Link
EP (1) EP0266940B1 (enExample)
JP (1) JPS63104929A (enExample)
AT (1) ATE83381T1 (enExample)
CA (1) CA1297788C (enExample)
DE (1) DE3783122T2 (enExample)
ES (1) ES2052579T3 (enExample)
GR (1) GR3006999T3 (enExample)
OA (1) OA08768A (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT99837A (pt) * 1990-12-21 1992-12-31 Schering Corp Processo para a preparacao de composicoes farmaceuticas contendo interferao alfa e metodo para administracao de interferao alfa por inalacao oral para tratar asma e doencas pulmonares proliferativas nao malignas
MX9307733A (es) * 1992-12-23 1994-06-30 Schering Corp Restauracion de la funcion inmunologica en pacientes asintomaticos de vih-positivo.
FR2713657B1 (fr) * 1993-12-13 1996-03-01 Transgene Sa Nouveaux vecteurs pour le traitement du sida.
PL2294066T3 (pl) 2008-04-28 2015-02-27 Janssen Pharmaceutica Nv Benzimidazole jako inhibitory hydroksylazy prolilowej
CA2853455C (en) 2011-10-25 2019-12-03 Janssen Pharmaceutica Nv Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
CN112245570A (zh) * 2019-07-22 2021-01-22 厦门特宝生物工程股份有限公司 一种基于干扰素的疾病治疗方法

Also Published As

Publication number Publication date
ATE83381T1 (de) 1993-01-15
GR3006999T3 (enExample) 1993-06-30
JPS63104929A (ja) 1988-05-10
EP0266940A1 (en) 1988-05-11
OA08768A (fr) 1989-03-31
DE3783122D1 (de) 1993-01-28
ES2052579T3 (es) 1994-07-16
CA1297788C (en) 1992-03-24
EP0266940B1 (en) 1992-12-16

Similar Documents

Publication Publication Date Title
DE69219782T2 (de) Verwendung eines thymosins bei der behandlung von hepatitis c
DE69333321T3 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
Sarin et al. Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone
DE69635671T2 (de) Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
DE68923932T2 (de) Hauttest und Testkit für AIDS.
DE69818445T2 (de) Verwendung von verbindungen die an ein zytoplasmatischen dipeptidase binden zur potenzierung des immunantworts
Blomgren et al. Interferon therapy in Hodgkin's disease: a case report
EP0495896B1 (de) Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
DE69327642T2 (de) Verfahren zur behandlung von viralen infectionen
Brivet et al. Pancreatic lesions in AIDS
Maller et al. Fatal myocarditis associated with ECHO virus, type 22, infection in a child with apparent immunological deficiency
DE68906735T2 (de) Pharmazeutische zubereitung zur behandlung von viruskrankheiten mit leber-extrakt.
Kempe et al. The pathogenesis of measles virus infection
Buimovici-Klein et al. Long-term follow-up of serum-interferon and its acid-stability in a group of homosexual men
DE3783122T2 (de) Verwendung von rekombiniertem menschlichem alpha-interferon zur herstellung eines arzneimittels zur behandlung des aids-virus.
Sundmacher et al. Human leukocyte and fibroblast interferon in a combination therapy of dendritic keratitis
DE68914990T2 (de) Verfahren zur inhibierung der wirkung des menschlichen immunschwäche-virus (hiv) in vivo.
DE69007571T2 (de) Peptidfragmente von HIV.
Higgins et al. Recombinant human interferon-γ as prophylaxis against rhinovirus colds in volunteers
DE68907569T2 (de) Mittel zur Behandlung oder Vorbeugung von Aids.
Preble et al. Interferon-Induced 2′–5′ Oligoadenylate Synthetase During Interferon-α Therapy in Homosexual Men with Kaposi's Sarcoma: Marked Deficiency in Biochemical Response to Interferon in Patients with Acquired Immunodeficiency Syndrome
Dianzani et al. Effects of IFNα on late stages of HIV-1 replication cycle
Terrell et al. Chronic eosinophilic myositis in a rhesus monkey infected with sarcosporidiosis
JPS60155121A (ja) 後天性免疫不全症候群の治療方法
Ohashi et al. Idiopathic CD4+ T-cell lymphocytopenia with verrucae, basal cell carcinomas, and chronic tinea corporis infection

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation